Cargando…

Metabolic syndrome and its components among obese (BMI ≥95th) Mexican adolescents

The aim of this study was to estimate the prevalence of metabolic syndrome (MS) and its components in obese Mexican adolescents and to compare the clinical, anthropometric, and biochemical characteristics between patients with and without MS by sex. We conducted a cross-sectional study with a sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Evia-Viscarra, Maria Lola, Rodea-Montero, Edel Rafael, Apolinar-Jiménez, Evelia, Quintana-Vargas, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioScientifica 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846108/
https://www.ncbi.nlm.nih.gov/pubmed/24145615
http://dx.doi.org/10.1530/EC-13-0057
Descripción
Sumario:The aim of this study was to estimate the prevalence of metabolic syndrome (MS) and its components in obese Mexican adolescents and to compare the clinical, anthropometric, and biochemical characteristics between patients with and without MS by sex. We conducted a cross-sectional study with a sample of 110 obese adolescents (boys and girls) from 8 to 16 years old (BMI ≥95th percentile), who were recruited in the pediatric obesity clinic of a third-level care hospital. A frequency analysis was used to estimate the prevalence of MS and its components, and the assessments were compared between the sexes and between the groups with and without MS using the Kruskal–Wallis test. The prevalence of MS was 62%. In order of prevalence, the following components of MS were observed in the sample: abdominal obesity (88%), high triglycerides (TG) (85%), low HDL-C (60%), hypertension (35%), and hyperglycemia (5%). In the groups with MS, hypertension (P<0.001), waist circumference (P=0.003), and TG (P=0.012) were significantly higher, and HDL-C (P<0.001) was significantly lower. In conclusion the prevalence of MS and its components is high among obese Mexican-Hispanic children. These findings show the importance of preventing and treating obesity in the early stages of life in order to decrease the incidence rates of cardiovascular disease and type 2 diabetes mellitus.